Aberrant expression of alternative splicing variants in multiple sclerosis – A systematic review
- 1 July 2019
- journal article
- review article
- Published by Elsevier in Autoimmunity Reviews
- Vol. 18 (7) , 721-732
Abstract
No abstract availableKeywords
Funding Information
- Sanofi Genzyme
- Bayer
- Daiichi Sankyo Company
- Genzyme
- Roche
- Novartis Pharma (024845, CFTY720DDE14T)
- Shire
This publication has 108 references indexed in Scilit:
- Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related lociNature Genetics, 2013
- Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunityProceedings of the National Academy of Sciences, 2013
- High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritisNature Genetics, 2012
- Pervasive haplotypic variation in the spliceo-transcriptome of the human major histocompatibility complexGenome Research, 2011
- Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility lociNature Genetics, 2010
- Expression of chemokine receptors on peripheral blood lymphocytes in multiple sclerosis and neuromyelitis opticaBMC Neurology, 2010
- Genome-wide association identifies multiple ulcerative colitis susceptibility lociNature Genetics, 2010
- Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetesNature Genetics, 2007
- Splice variation in the cytoplasmic domains of myelin oligodendrocyte glycoprotein affects its cellular localisation and transport1Journal of Neurochemistry, 2007
- Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosisJournal of Clinical Investigation, 2006